Update shared on11 Sep 2025
Fair value Increased 0.74%Analysts have modestly raised IQVIA’s price target to $215.89, citing strong B2B metrics, business diversification, and resilience in core segments despite sector headwinds and macroeconomic uncertainty.
Analyst Commentary
- Bullish analysts cite IQVIA’s stronger business-to-business metrics, workforce stability, and lower customer concentration as reasons for outperformance and insulation against pharma sector restructurings, supporting higher valuation multiples.
- Bullish analysts highlight resilience relative to peers in the contract research organization sector and effective diversification through technology and analytics, pointing to lower business risk.
- Improved demand trajectory in pharma and biotech services, along with strong recent quarterly results, especially in R&DS and TAS segments (analytics, consulting, and tech), are driving upward revisions to price targets.
- Some analysts note margin pressures but point to a supportive environment and market share gains as offsetting factors, supporting higher price targets despite sector headwinds.
- Bearish analysts express concerns about policy uncertainty, macroeconomic challenges, and limited near-term visibility, resulting in soft forecasts and cautious adjustments to estimates, while noting CRO sector valuations remain historically attractive.
What's in the News
- Michael J. Fedock will succeed Ronald E. Bruehlman as CFO, effective February 28, 2026, as part of a planned succession; Bruehlman will transition to Senior Advisor to the CEO.
- IQVIA announced a strategic collaboration with Flagship Pioneering to accelerate life sciences company development using advanced analytics, AI, and clinical trial expertise.
- IQVIA formed a comprehensive partnership with Kexing Biopharm to support global clinical development and commercialization, especially in Europe and regulated markets.
- The company repurchased 4.1 million shares for $607 million, reaching a cumulative buyback of 91.6 million shares (52.52%) under the ongoing program.
- IQVIA updated 2025 revenue guidance to $16.1–$16.3 billion, factoring in a $100 million COVID-related step-down, forex tailwinds, and acquisition contributions; Q3 2025 revenue is expected between $4.025–$4.1 billion.
Valuation Changes
Summary of Valuation Changes for IQVIA Holdings
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $214.32 to $215.89.
- The Future P/E for IQVIA Holdings remained effectively unchanged, moving only marginally from 21.06x to 21.21x.
- The Consensus Revenue Growth forecasts for IQVIA Holdings remained effectively unchanged, at 5.4% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.